The important role of circulating IGF-I in cancer development was demonstrated in vivo using liver-specific-IGF-I deficient (LID and iLID) mouse models where decreased mammary tumor incidence and progression and reduced colon adenocarcinoma growth and metastasis were documented [21,22]. This evidence concerns the gene IGF1 and cancer.